Blood plasma derivatives have a wide range of applications thus increasing their demand in the market. They are used in various diseases like HIV, hepatitis B and Hepatitis C. Plasma derivatives are collected from large number of donors for their use in patients suffering from life threatening diseases. Hence the importance of blood plasma derivatives have increased in healthcare. The global market of Blood Plasma Derivatives is expected to reach US$ 58.2 billion in 2023 from US$ 30.5 billion in 2016 with a CAGR of approximately 7.52% during the forecast period 2017-2023.
Global Blood Plasma Derivatives Market – Overview
The global blood plasma derivatives market is growing mainly due to the increasing demand for plasma derived products. According to a recent study report published by the Market Research Future, The global blood plasma derivatives market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
Plasma is a fluid part of the blood that contains blood cells, and protein responsible for blood clotting. Plasma derivatives are obtained from specific plasma proteins by the process of fractionation. The derivatives are then solvent detergent-treated or heat-treated to kill certain viruses. The most common plasma derivative includes factor IX concentrate, factor VIII concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, immune globulins, Alpha 1-Proteinase inhibitor concentrate, albumin, and anti-thrombin III concentrate. Blood plasma derivative widely used clinically to treat various conditions such as hemophilia A, hemophilia B, HIV, hepatitis B, hepatitis C, thrombocytosis, and others.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/1325
Notably, rising demand for plasma derivative based therapies is the key factor driving the blood plasma derivatives market. According to a study published in the Journal of Blood Medicine in 2016, it is found that FIX replacement therapy which includes plasma-derived protein are successful in the reduction of disability, and bleeding from hemophilia B. Based on the prevalence rate, hemophilia and von willebrand disease (VWD) are the most common bleeding disorders in the Middle East and Africa. According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH),
in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years.
Global Blood Plasma Derivatives Market – Competitive Analysis
Grigols (Spain), Baxter International Inc. (US), Octapharma AG (Switzerland), CSL Limited (Australia), Kedrion S.p.A (Italy), Bain Capital, LLC (US), Biotest AG (Germany), Fusion Healthcare (India), SK Plasma Co., Ltd. (South Korea) are some of the prominent players at the forefront of competition in the blood plasma derivatives market and are profiled in MRFR Analysis.
The global blood plasma derivatives market is currently dominated by few players.
Grigols is one of them by holding a strong share in the market. The company’s stronghold is largely attributed to its innovative and sustainable products.
Grigols aoperates in three major divisions i.e. Bioscience, Diagnostic and Hospital. On November 17, 2017 Grigols received FDA approval for a new genetic test used to detect alpha-1 antitrypsin deficiency.
On November 11, 2013, Grifols acquired blood transfusion testing unit of Novartis AG for USD 1.68 billion. In the year 2016, Grifols has also acquired NAT (Nucleic Acid Testing) donor screening unit of Hologic for USD 1,850 million.
Baxter is also one of the leading player in blood plasma derivatives market. Baxter International Inc., the US based biopharmaceutical company, operates in two major segments, i.e. Hospital Products and Renal. Baxter’s product Bebulin (Factor IX Complex) is specifically used for the prevention, of hemorrhagic episodes in case of hemophilia B. Bebulin may carry a risk of transmitting infectious agents, such as viruses and, Creutzfeldt‐Jakob disease (CJD) agent.
On July 27, 2017, Baxter International Inc. completed the acquisition of Claris Injectables Limited for approximately USD 625 million. The main motive of acquisition is the expansion of generic pharmaceuticals.
On June 06, 2017, ADMA Biologics, Inc., a biopharmaceutical company, has acquired therapy business unit of Biotest Pharmaceuticals. As a result of this, ADMA acquired two FDA approved products i.e. Nabi-HB™, and and BIVIGAM™.
Global Blood Plasma Derivatives market has been segmented on the basis of type which includes albumin, anti-thrombin, intravenous immunoglobulin (IVIG), fresh frozen plasma (FFP) and others. Others types are Factor VII, Factor IX and Alpha 1 proteinase inhibitor concentrate. On the basis on application the market is segmented into Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others. Other application includes Von Willebrand disease. End users include hospitals, clinics, diagnostic centers, blood transfusion centers and others.
Regional Analysis of Blood Plasma Derivatives Market:
Globally, Blood Plasma Derivatives market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa. North America is the largest market for syringe and needle.
The North American market for Blood Plasma Derivatives is expected to grow at a CAGR of 4.25% which is expected to reach at US$ 35.50 billion from US$ 20 billion in 2016 by the end of the forecasted period. Awareness regarding use of plasma derivatives for patients suffering from infectious diseases drive this market in North America.
Europe is the second-largest market for Blood Plasma Derivatives which is expected to grow at a CAGR of 3.8%. Extensive research on safe blood transfusion in healthcare organizations and research laboratories favor the growth of this market in Europe. Whereas Asia Pacific is expected to be the fastest growing market for Blood Plasma Derivatives market. India is expected to be the emerging and fastest growing market. Demand for plasma derivatives for inactivation of HIV favor the demand of plasma derivatives in Asia-pacific. The market shows steady growth in Middle East and Africa.
Access Report Details @ https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312